CONNECT: COvid-19 aNd TechNology - thE Impact on Clinical Trial Patients
Study Details
Study Description
Brief Summary
This is a 2 part qualitative study involving a questionnaire (part 1) and focus group discussions (part 2).
The purpose of the study is to evaluate how patients' attitudes to technology in the oncology clinical trials setting since the start of the Coronavirus pandemic in 2020, and to assess how their use of technology has changed during this time.
Part 1 of the study will be conducted via a self-report questionnaire to 100-140 cancer patients involved in clinical trials at The Christie NHS Foundation Trust over a 2 month period. Following this, three focus groups with a maximum of 8 participants in each group will take place to further assess patients' experiences with technology during the pandemic.
Participants may take part in part 1 or part 2 only, or in both.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Clinical trial involvement is more resource-intensive than receiving standard of care treatment and often results in more frequent hospital visits for patients. To reduce the risk of patients to COVID-19, there has been a shift towards reducing on-site visits with increased use of technology e.g. virtual visits. Patients may have also been using devices at home to aid in their care, including digital devices, mobile applications, smart watches and, rarely, trial-specific devices, to monitor aspects of their own health.
Our project will explore the impact that the coronavirus pandemic has had on clinical trial patients and how they feel technology could help or create barriers in their future care.
In order to quantify how clinical trial visits have changed and to evaluate patient's attitudes to the increasing use of technology in clinical trials, we will be disseminating questionnaires to 100 patients currently on clinical trials over a 2 month period. We will follow these up with three virtual focus group discussions with 8 participants in each to delve further into patients' experiences.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Questionnaire Observational |
Other: No intervention
This is an observational study
|
Focus Group Observational |
Other: No intervention
This is an observational study
|
Outcome Measures
Primary Outcome Measures
- To evaluate patients' attitudes to technology in the clinical trial setting since the coronavirus pandemic 2020. [9 months]
Secondary Outcome Measures
- To assess changes in patients use of technology in oncology clinical trials prior to and since the coronavirus pandemic 2020. [9 months]
Other Outcome Measures
- To determine how coronavirus pandemic has impacted the use of technology in the delivery of oncology trials for patients. [9 months]
- To assess the relationship between socioeconomic status and age and how it impacts the use of technology [9 months]
- To evaluate the challenges and opportunities of using technology in the future in the delivery of clinical trials technologies for future patient care. [9 months]
- To assess the role of healthcare technologies for future patient care. [9 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
-
Patients have to be 18 years of age or older.
-
Patients have to be currently enrolled on a phase I, II or III cancer related clinical trial within the Christie NHS Foundation Trust
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
-
Unable to understand and converse in English for the focus group session.
-
Patient not currently involved in a phase I, II or III clinical trial
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | The Christie NHS Foundation Trust | Manchester | Greater Manchester | United Kingdom | M20 4BX |
Sponsors and Collaborators
- The Christie NHS Foundation Trust
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CFTSp197